An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

NPPA asks cos to revise prices of 17 drugs following BCD exemption: Gireesh Babu, New Delhi Thursday, February 12, 2026, 08:00 Hrs [IST] The National Pharmaceutical Pricing Author ...

Mendus AB (STU:1YG0) showcases positive trial data and strategic financial moves, despite facing ongoing financial hurdles and market uncertainties.

Exploring the combination with atezolizumab and radiation therapy Study led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 ...

Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...

Sellas Life Sciences faces a high bar with its Phase 3 REGAL trial for GPS in AML second remission. REGAL’s ambitious hazard ratio target, open-label design, and heterogeneous control arm raise ...

Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

This required urgent treatment with a blood thinner, but risked causing dangerous bleeding as his blood platelets were seriously low due to AML.